Adriana C. Girardi received a B.A. in Pharmacology and Biochemistry (1996) and a Ph.D. (2002) in Physiology at University of São Paulo. From 2002 to 2005, she was a postdoctoral fellow in the Aronson lab (Department of Internal Medicine, Section of Nephrology, Yale University). Currently, she is a principal investigator in the Laboratory of Genetics and Molecular Cardiology, Incor, HC-USP and Professor at FMUSP. She has experience in Renal Physiology, Cardiorenal Pharmacology and Biochemistry. Her major scientific interest is understanding blood pressure regulation and cardiovascular disease. Recently, her research group has investigated how therapies for diabetes affect cardiovascular disease progression and hypertension. javascript:void(0) (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Sodium/glucose cotransporter 2 (SGLT2) inhibitors, also known as gliflozins, have emerged as potent therapeutic agents for improving glycemic control by suppressing glucose reabsorption in the renal proximal tubule. Originally designed for managing diabetes, gliflozins exhibit additional benefits, such as reducing cardiovascular mortality and heart failure (HF) hospitalization, irrespecti…
Patients with chronic kidney disease (CKD) face an increased risk of cardiovascular complications, driven by factors such as uremic toxins that contribute to reactive oxygen species generation and inflammation, ultimately leading to endothelial dysfunction, cardiac ischemia, cardiac remodeling, and arrhythmia. Despite increasing awareness of uremic toxins and their detrimental effects, cu…
Altogether, the three subprojects that integrate this proposal aim to elucidate novel molecular mechanisms underlying the renal tubular actions of antidiabetic drugs and their pharmacological targets. The first subproject intends to explore the molecular basis of the renal tubular effects of gliflozins. More specifically, we will investigate the mechanisms by which the pharmacological and…
Clinical evidence indicates that hypertensive patients are highly susceptible to infection and the severity of COVID-19, a disease caused by the new SARS coronavirus SARS-Cov-2. The SARS-CoV-2 requires the host protein angiotensin-converting enzyme-2 (ACE2), as a receptor, and the serine protease TMPRSS2, for S protein priming, to gain intracellular entry in the lungs, among other organs …
Dipeptidyl peptidase 4 (DPP4) inhibitors are antidiabetic agents that exert renoprotective effects, beyond glucose control in humans and in experimental models of cardiovascular and renal diseases. DPP4 inhibition reduces Na+/H+ exchanger isoform 3 (NHE3)-dependent sodium reabsorption in the renal proximal tubule and this inhibitory effect is associated with blood pressure lowering effect…
(Only some records are available in English at this moment)
Sodium/glucose cotransporter 2 (SGLT2) inhibitors, also known as gliflozins, have emerged as potent therapeutic agents for improving glycemic control by suppressing glucose reabsorption in the renal proximal tubule. Originally designed for managing diabetes, gliflozins exhibit additional benefits, such as reducing cardiovascular mortality and heart failure (HF) hospitalization, irrespecti…
A series of clinical and experimental evidence documents the importance of the kidneys in the pathogenesis of arterial hypertension. The extracellular volume and sodium ion balance are maintained through the regulation of a series of sodium transporters expressed in the apical membrane of the renal tubule. Consequently, changes in these transporters' number and/or intrinsic activity affec…
Na+/glucose cotransporter type 2 inhibitors (iSGLT2), also known as gliflozins, confer cardiorenal benefits, the precise mechanisms of which remain incompletely understood. Originally developed for treating type 2 diabetes mellitus (T2D), it was unexpectedly observed that these drugs reduce hospitalizations for heart failure (HF) and mortality from cardiovascular causes, irrespective of a…
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by intestinal L cells whose primary function involves the maintenance of glycemic homeostasis. However, different studies have consistently demonstrated that GLP-1 receptor (GLP-1R) agonists, drugs used to treat type 2 diabetes mellitus, exert several extraglycemic effects, including increased diuresis and natriuresis and red…
Gliflozins, in addition to proving to be effective in the treatment of type 2 diabetes mellitus (T2DM), have been demonstrating significant improvements in cases of heart failure (HF) and chronic kidney disease (CKD). However, the reported clinical benefits for gliflozins cannot be explained solely by SGLT2 inhibition in the proximal renal tubule. In this project, we intend to isolate and…
(Only some records are available in English at this moment)
The distal convoluted tubule (DCT) is crucial for regulating blood pressure and magnesium homeostasis, highlighting its role in cardiovascular and kidney health. Both genetic and acquired disorders affecting the DCT can lead to renal sodium and magnesium loss. Hypomagnesemia, characterized by low serum magnesium levels, is also commonly observed in patients treated with the anti-tumor dru…
Dipeptidyl peptidase 4 (DPP4) inhibitors are antidiabetic agents that exert renoprotective effects beyond glucose control in humans and experimental models of cardiovascular and renal diseases. DPP4 inhibition reduces Na+/H+ exchanger isoform 3 (NHE3)-dependent sodium reabsorption in the renal proximal tubule, and this inhibitory effect is associated with blood pressure lowering effects i…
A isoforma 3 do trocador Na/H (NHE3) está presente na membrana apical do túbulo proximal renal e medeia a reabsorção da maior parte do NaCl e do NaHCO3 neste segmento do néfron. Dada a sua importância na homeostase dos fluidos corporais, o NHE3 é fortemente regulado por uma ampla gama de efetores através de múltiplos mecanismos moleculares. A rápida regulação da atividade do NHE3 pode oco…
| 3 / 3 | Ongoing research grants |
| 14 / 9 | Completed research grants |
| 3 / 3 | Ongoing scholarships in Brazil |
| 38 / 28 | Completed scholarships in Brazil |
| 1 / 1 | Ongoing scholarships abroad |
| 2 / 2 | Completed scholarships abroad |
| 61 / 46 | All research grants and scholarships |
| Associated processes | |
CV Lattes
ORCID